Literature DB >> 2530882

Cardioprotective effects of amlodipine in the ischemic-reperfused heart.

P T Hoff1, Y Tamura, B R Lucchesi.   

Abstract

Amlodipine is a dihydropyridine derivative belonging to the group of pharmacologic calcium entry blocking agents and is characterized as having a slow onset and relatively long duration of action with minimal effects on cardiac electrophysiology and myocardial contractility. The protective effect of amlodipine was studied in isolated blood-perfused feline hearts made globally ischemic for 60 minutes followed by reperfusion for 60 minutes. Ischemic-induced alterations of left ventricular developed pressure and complicance were monitored. In 11 control and 7 drug-treated hearts, amlodipine produced significant decreases in myocardial oxygen consumption (6.2 +/- 0.4 to 4.4 +/- 0.4 ml oxygen/min/100 g) and coronary vascular resistance, as assessed by changes in perfusion pressure (120 +/- 1 to 100 +/- 4 mm Hg). Amlodipine administered before the onset of global ischemia decreased the development of ischemic contracture as reflected by a progressive increase in resting left ventricular diastolic pressure. The return of contractile function, 60 minutes afer reperfusion, improved significantly in the amlodipine-treated group compared with controls, and there was better maintenance of the tissue concentration of Na+, Ca2+ and K+. A canine model of regional myocardial ischemia (90 minutes) followed by 6 hours of reperfusion was used to assess the cardioprotective effects of amlodipine, 150 micrograms/kg, administered 15 minutes before reperfusion. Infarct size, expressed as a percentage of the area at risk, was smaller in the amlodipine-treated group (n = 10) than in the control group (n = 10) (34.5 +/- 3.8% vs 45.9 +/- 2.8%, p = 0.027). Risk region size did not differ between groups and both groups were comparable with respect to the hemodynamic parameters of heart rate, blood pressure and rate-pressure product. Amlodipine prevented the gradual reduction in coronary blood flow observed in the control group. It is concluded that amlodipine reduces myocardial ischemic injury by mechanism(s) that may involve a reduction in myocardial oxygen demand as well as by positively influencing transmembrane Ca2+ fluxes during ischemia and reperfusion.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2530882     DOI: 10.1016/0002-9149(89)90967-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Comparison of the effects of different magnesium administration times on infarct size.

Authors:  Diego R Martínez Demaría; Horacio E Cingolani; Susana M Mosca
Journal:  Exp Clin Cardiol       Date:  2003

2.  Effects of felodipine on the ischemic heart: insight into the mechanism of cytoprotection.

Authors:  R Ferrari; A Cargnoni; P Bernocchi; G Gaia; M Benigno; E Pasini; P Pedersini; C Ceconi
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

Review 3.  Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

Authors:  D Murdoch; R C Heel
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 4.  Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease.

Authors:  M Haria; A J Wagstaff
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 5.  Targeting calcium transport in ischaemic heart disease.

Authors:  M A Hassan Talukder; Jay L Zweier; Muthu Periasamy
Journal:  Cardiovasc Res       Date:  2009-07-29       Impact factor: 10.787

6.  Efficacy of amlodipine besilate therapy for variant angina: evaluation by 24-hour Holter monitoring.

Authors:  K Watanabe; T Izumi; Y Miyakita; S Koyama; M Ohshima; T Inomata; M Suzuki; M Takahashi; A Shibata
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.